

FAILURE MODE EFFECT ANALYSIS (FMEA) PROJECT **ON ADMINISTRATION OF CONCENTRATED KCL**

INFUSION IN CICU

KK Women's and **Children's Hospital** SingHealth

A.N.LEE¹, Y.K.KONG¹, S.L.ANG¹, Y.H.CHAN¹, S.K.LEE². N.L.PANG³, M. K. SEOW & S.C.NEO ¹CHILDREN'S INTENSIVE CARE UNIT, ²DIVISION OF NURSING, ³MEDICAL AFFAIRS, ⁴PHARMACY & ⁵ISD KK WOMEN'S AND CHILDREN'S HOSPITAL, SINGAPORE

INTRODUCTION

Intensivists, Cardio-thoracic surgeons and Cardiologists all agree that correction of hypokalemia is crucial in critically ill children. Therefore, in the Children Intensive Care Unit (CICU), concentrated KCL 1:1 dilution is commonly prescribed for cardiac patients for correction of low serum potassium. When fluid intake is restricted, small volume infusions are necessary and KCL will be diluted with minimal diluent. However, any medication error related to concentrated KCL infusion can be potentially fatal. This concern was raised to the Patient Safety

FMEA Methodology

New Processes

Concentrated KCL Infusion Flow Chart – Solutions

Council. A taskforce was formed to review this process and to look for solutions to prevent fatal errors related to administration of concentrated KCL.

OBJECTIVE

The objective was to minimize the chance of any loopholes within the KCL administration process which might potentially compromise patient safety. We also aim to quantify the risk involved in control failure so as to enable us to provide the correct type of damage control.

METHODOLOGY: FAILURE MODE EFFECT ANALYSIS (FMEA)

FMEA is a prospective risk assessment tool designed to promote patient safety by mapping out the process of care, follows by identifying potential failures that may occur in this process, in order to understand how and why errors or failures occur (Shebl et al, 2012). Using the FMEA model, the group analysed the entire administration process of IV KCL. Potential failure modes that might impact on patient safety in the various sub-processes were identified as requiring improvements. The group then listed the appropriate safety measures that was necessary to prevent potential medication errors pertaining to these processes.

CONCLUSION

The new process allows CICU doctors to place high-risk KCL 7.45% (1mmol/mL) Injection (1 in 1 dilution) order with automatic calculated dosage and dose rate checking function in place. With the development of safety guidelines on the use of concentrated KCL, we have achieved our goal of eliminating the potential risks that can result in fatal error in this group of patients.







Potential Risk Identified: medication error arising from concentrated KCL can be FATAL





to refer when ordering.

Prescription